Pharma Industry

The company, which launched its blockbuster weight-loss drug Mounjaro in India this year, currently does not operate its own manufacturing facility in the country

India bulk drug makers start preparing for Ozempic patent expiry

Drugmakers in India — the world’s largest supplier of non-patented medicines — aim to tap what could be a $94 billion global opportunity by 2035

Pharma products face stricter scrutiny over drug brand name confusion: Report

Brands with similar or identical names will be prohibited from being marketed. Drug manufacturers will soon be required to upload detailed formulation information alongside their brand names to a government portal.

Budget wish list: Pharma industry seeks tax benefits, effective intellectual property rights regime

Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.

Entero IPO: Should investors pop the flotation pill?

The company will have to scale up its top line manifold to be able to protect its profitability

Cipla: Sailing well on the US pharma business front

The company’s chronic portfolio continues to gain strength and the US base business has moved to a new orbit. This is supportive for medium-term earnings growth, which makes us constructive on the business.

Hetero to invest Rs 1,000 crore in AP over two years to expand pharma business

Speaking at Global Investors Summit 2023 here, he said post-Covid pandemic, more countries are looking at India as a partner of choice in pharmaceutical sector, and Andhra Pradesh is ideally placed to take advantage because of a well-established ecosystem.

Pharma sector gets first tranche of payment under under PLI scheme

Dr Reddy's Laboratories Limited, Biocon Limited, Strides Pharma Science Limited and Premier Medical Corporation Private Limited have been granted the incentives in the first phase

India’s pharma industry’s problems need to be fixed, now!

The problem is that the government is never transparent about what remedial measures it has taken to address complaints raised against pharma companies. Instead, it often obfuscates, deflects, or threatens academics who speak about the issue

Research crucial for Indian pharma industry to move from ‘volume’ to ‘value’: Mansukh Mandaviya

In order to provide impetus to the research in pharmaceutical sector, Mandaviya said that the union government has drafted a separate policy for research and development.

Govt wants to ease compliance burden on pharma industry: Mansukh Mandaviya

Addressing an event of the Indian Drug Manufacturers’ Association (IDMA), Mansukh Mandivya, who is also the Minister for Health and Family Welfare, said that the Narendra Modi-led government at the Centre is not only pro-poor and pro-farmer but "industry-friendly" as well.

Indian pharma industry estimated to grow 9-11% in 2021-22: ICRA

In a sample of 21 Indian pharmaceutical companies, ICRA said revenue growth was moderate at 6.4 per cent in the second quarter of FY22, down from 16 per cent in the first quarter of 2021-22.

Mansukh Mandaviya urges pharma industry to make India a manufacturing hub

Addressing the Investor Summit on 'Opportunities & Partnerships in Pharma & Medical Devices', the minister spoke about the government’s pro-industry reforms and efforts to make India the best investment destination in the world.

Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency"

His advice to young leaders: "Focus on relationships and building trust with your customers, your partners and your employees."

Gland Pharma’s focus on injectables yields superior growth

Gland Pharma’s revenue growth surpassed that of frontline drug companies in FY21. It is expected to outpace industry majors in the current fiscal too

I am sure global pharma industry will support India's WTO proposal of IP waiver for COVID-19: Piyush Goyal

In October 2020, India and South Africa submitted a proposal suggesting a waiver for all WTO (World Trade Organisation) members on the implementation, application and enforcement of certain provisions of the TRIPS Agreement in relation to the prevention, containment or treatment of COVID-19.

Indian pharma firms go local seeking to end reliance on China

Though India is known as the pharmacy of the world for its massive production capacities of both generic drugs and vaccines, China accounted for half of its API needs in 2019 from nearly nothing three decades ago, industry data shows.

Budget 2021 could be the vaccine for the pharmaceutical industry

Given the government’s ambition to make India a $5 trillion economy in the next five years, pharmaceutical and life science could be the ‘target sector’ in Budget 2021

Coronavirus pandemic | Centre to expedite clearances to bulk drug projects to fight COVID-19

The notification has been sent to the Central Pollution Control Board, Expert Appraisal Committee and pollution control boards in all states and Union territories.

3-Point Analysis | API export restriction: Takeaways for pharma industry

Moneycontrol's Sakshi Batra does a 3-Point Analysis to understand what it means for the Indian pharma industry.

Indian pharma industry likely to grow at 10-13% in FY'21: ICRA

The expected growth in the next financial year is on the back of healthy demand from the domestic market given increasing spend on healthcare along with improving access, Icra said in a statement.

Editor's Take | Budget 2020: The pharma industry's wishlist

Shraddha Sharma gets in conversation with Corporate Bureau Chief Prince Thomas to find out the expectations of the phama sector from Finance Minister Nirmala Sitharaman in Budget 2020.

NPPA issues notices to Lupin, Ranbaxy, others for selling FDCs without price approval

“These companies have launched formulations by altering a scheduled formulation with strength/dosage other than as specified in DPCO, 2013 and secondly in combination with other non-scheduled medicines without even applying for price approval from NPPA as required under Para 1 (2) of DPCO, 2013,” NPPA said.

Pharma: Here's what all happened in the sector last week

Here's what happened in pharma last week

Budget 2017: Weighted deductions for incurring pharma R&D should continue

R&D/clinical trial services performed in India are liable to service tax at the rate of 15% even when the recipient of service is situated outside India. To lower the cost of provision of such services and to boost innovation in the country and make such services globally competitive, it is important to provide for some sort of exemption.